Kairos Pharma, LTD.
No SEC Form 4 filings for $KAPA in the last 30 days.
See all $KAPA insider activity →Kairos Pharma reported Phase 2 interim data showing median progression-free survival of 17.7 months for ENV-105 plus apalutamide vs 2 months for apalutamide alone (P=0.0008). The trial protocol was modified to enroll patients earlier and expand the eligible population, with trial completion targeted for Q4 2027. ENV-105 is a CD105 antibody aimed at reversing drug resistance.
Kairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressin
Kairos Pharma (KAPA) announced a 1-for-7 reverse stock split effective September 1, 2026. The company is developing several cancer treatments, with key updates expected in Q3 2026. KAPA's stock has hit a 52-week low, trading at $0.22, down 21.46%.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning KAPA (Kairos Pharma, LTD.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent KAPA coverage spans financial news, corporate actions and market movers.
Positive Phase 2 interim results are likely to lift the stock as investors price in potential later-stage success.
Positive trial data is likely to lift KAPA shares as investors price in a potential breakthrough therapy.
The reverse split will reduce share count, potentially improve price perception and liquidity, but may also trigger short covering and volatility.
The filing discloses a new research-support agreement structure with Bayer, including sponsor obligations, drug supply terms, and long confidentiality/IP provisions.
Positive interim safety readout for ENV-105 in Phase 1, plus supportive efficacy signal in Phase 2, is a near-term catalyst for sentiment and risk appetite in this microcap biotech.
AlphAI scores every news story that mentions KAPA with an AI model for sentiment and relevance, and aggregates insider trades from Kairos Pharma, LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kairos Pharma reported Phase 2 interim data showing median progression-free survival of 17.7 months for ENV-105 plus apalutamide vs 2 months for apalutamide alone (P=0.0008). The trial protocol was modified to enroll patients earlier and expand the eligible population, with trial completion targeted for Q4 2027. ENV-105 is a CD105 antibody aimed at reversing drug resistance.
1 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressin
2 min readKairos Pharma (KAPA) announced a 1-for-7 reverse stock split effective September 1, 2026. The company is developing several cancer treatments, with key updates expected in Q3 2026. KAPA's stock has hit a 52-week low, trading at $0.22, down 21.46%.
2 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 NOTE: Certain identified information has been excluded from this exhibit and replaced with [***] because it is both (i) not material and (ii) the type of information the Company treats as private or confidential. Agreement for the Support
2 min readKairos Pharma (NYSE:KAPA) shares rose 22.64% to $0.39 in after-hours after the company reported positive interim Phase 1 safety data for ENV-105. Kairos said none of 13 treated patients had serious adverse events. ENV-105 is being tested with AstraZeneca’s Tagrisso in EGFR-mutated NSCLC and in Phase 2 for castrate-resistant prostate cancer.
6 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001962011 0001962011 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor
3 min readENV-105 shows no Grade 3 or 4 toxicities in the early Phase 2 mCRPC trial. Kairos Pharma stock volume soars to 221 million vs. 874K average after safety data release. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Kairos Pharma, Ltd.
2 min readU.S. stocks traded mixed midway through trading, with the Nasdaq gaining more than 100 points on Tuesday. The Dow traded down 0.57% to 44,204.33 while the NASDAQ gained 0.71% to 20,786.86. The S&P 500 also rose, gaining, 0.01% to 6,269.15. Information technology shares jumped by 1.6% on Tuesday.
3 min read
